Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Good manners for the pharmaceutical industry

M Gore, R A'Hern, K Swenerton

    Lancet (London, England)
    |August 2, 1997
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.

    Annals of oncology : official journal of the European Society for Medical Oncology·2020
    Same author

    Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2019
    Same author

    The impact of effective systemic therapies on surgery for stage IV melanoma.

    European journal of cancer (Oxford, England : 1990)·2018
    Same author

    Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2018
    Same author

    Cervical Spine Fractures in Patients Undergoing Palliative Radiotherapy to the Cervical Spine: Implications for Practice.

    Clinical oncology (Royal College of Radiologists (Great Britain))·2018
    Same author

    First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma.

    Annals of oncology : official journal of the European Society for Medical Oncology·2018